Recursion
Founded Year
2013Stage
Corporate Minority - P2P - II | IPOTotal Raised
$509.79MMarket Cap
1.60BStock Price
7.39Revenue
$0000About Recursion
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.
Loading...
Loading...
Research containing Recursion
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Recursion in 9 CB Insights research briefs, most recently on Nov 1, 2023.
Aug 29, 2023
The pharma AI market map
Aug 10, 2023
The oncology tech market map
Aug 1, 2023
The state of healthcare AI in 5 charts
Expert Collections containing Recursion
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Recursion is included in 7 Expert Collections, including AI 100.
AI 100
299 items
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
Conference Exhibitors
5,501 items
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Artificial Intelligence
10,987 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
10,585 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Recursion Patents
Recursion has filed 30 patents.
The 3 most popular patent topics include:
- molecular biology
- biotechnology
- drug discovery
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/18/2022 | 10/17/2023 | Motivation, Branches of psychology, Bioinformatics, Applied psychology, Molecular biology | Grant |
Application Date | 7/18/2022 |
|---|---|
Grant Date | 10/17/2023 |
Title | |
Related Topics | Motivation, Branches of psychology, Bioinformatics, Applied psychology, Molecular biology |
Status | Grant |
Latest Recursion News
Nov 15, 2023
Graphic designer/iStock via Getty Images AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ: RXRX ) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA: ARKK ), managed by famous stock picker Cathie Wood, bought ~3.8M of company shares. Nearly 4.8M Recursion ( RXRX ) shares have changed hands so far, compared to the 65-day average of 3.6M, as the stock gained for the fourth straight session to reach the highest level since September. Recursion’ ( RXRX ) peers in AI drug discovery are also trading higher. In recent weeks, Cathie Wood-managed ARK Invest ETFs have become increasingly bullish on Salt Lake City, Utah-based biotech. ARK Innovation ETF ( ARKK ) and ARK Genomic Revolution (BATS: ARKG ) bought ~188.9K RXRX shares this week alone. The investments coincide with rising investor interest in AI-led drug discovery. A $50M investment from chip maker Nvidia ( NVDA ) sent Recursion ( RXRX ) shares sharply higher in July, sparking a rally among its peers.
Recursion Frequently Asked Questions (FAQ)
When was Recursion founded?
Recursion was founded in 2013.
Where is Recursion's headquarters?
Recursion's headquarters is located at 41 South Rio Grande Street, Salt Lake City.
What is Recursion's latest funding round?
Recursion's latest funding round is Corporate Minority - P2P - II.
How much did Recursion raise?
Recursion raised a total of $509.79M.
Who are the investors of Recursion?
Investors of Recursion include NVIDIA, Baillie Gifford, Mubadala Investment Company, Laurion Capital Management, Invus Group and 30 more.
Who are Recursion's competitors?
Competitors of Recursion include Pepper Bio, Aitia, Terray Therapeutics, Gero, BIOS Health and 7 more.
Loading...
Compare Recursion to Competitors
Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
Loading...